Circulating MiRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Jansen, Christian ^a   Reiberger, Thomas ^b   Huang, Jia ^c   Eischeid, Hannah ^c   Schierwagen, Robert ^a   Mandorfer, Mattias ^b   Anadol, Evrim ^a   Schwabl, Philipp ^b   Schwarze Zander, Carolynne ^a   Warnecke Eberz, Ute ^c   Strassburg, Christian P ^a   Rockstroh, Jürgen K ^a   Peck Radosavljevic, Markus ^b   Odenthal, Margarete ^c   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; LOPINAVIR; MICRORNA 122; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; MICRORNA; MIRN122 MICRORNA, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELASTOGRAPH; ELASTOGRAPHY; FEMALE; GENETIC CORRELATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER FIBROSIS; LIVER STIFFNESS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NONHUMAN; PORTAL HYPERTENSION; PREDICTIVE VALUE; PRESSURE GRADIENT; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RIGIDITY; RNA ANALYSIS; RNA GENE; RNA ISOLATION; SIMIAN VIRUS 40; UPREGULATION; VENOUS PRESSURE; BLOOD; COMPLICATION; INJURIES; LIVER; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD PRESSURE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; MICRORNAS; MIDDLE AGED; PORTAL PRESSURE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922365948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116768     Document Type: Article

References (41)

1. UNAIDS (2013) in Global Report 2013.
2. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL (2001) Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 285: 1308-1315. doi: 10.1001/ jama.285.10.1308 PMID: 11255385
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29. doi: 10.1016/S0140-6736(03) 13802-0 PMID: 12853195
4. Klein MB, Rollet-Kurhajec KC, Moodie EE, Yaphe S, Tyndall M, et al. (2014) Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS 28: 1957-1965. doi: 10.1097/QAD.0000000000000377 PMID: 25259703
5. van Beek JH, de Moor MH, de Geus EJ, Lubke GH, Vink JM, et al. (2013) The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet 43: 329-339. doi: 10.1007/s10519-013-9593-y PMID: 23580007
6. Marcellin F, Lorente N, Demoulin B, Carrieri MP, Suzan-Monti M, et al. (2014) Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sex Transm Infect.
7. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, et al. (2005) Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 40: 588-593. doi: 10.1086/427216 PMID: 15712082
8. Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, et al. (2010) HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 17: 400-409. doi: 10.1111/j.1365-2893.2009.01197.x PMID: 19780945
9. Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, et al. (2014) Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 160: 369-379. doi: 10.7326/M13-1829 PMID: 24723077
10. Merchante N, Merino E, Rodriguez-Arrondo F, Tural C, Munoz J, et al. (2014) HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. AIDS 28: 41-47. doi: 10.1097/QAD.0000000000000005 PMID: 24056067
11. Brau N (2005) Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Semin Liver Dis 25: 33-51. doi: 10.1055/ s-2005-864780 PMID: 15731996
12. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, et al. (2011) Considerable undertreatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 16: 815-824. doi: 10.3851/IMP1831 PMID: 21900713
13. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, et al. (2005) HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41: 779-789. doi: 10.1002/hep.20626 PMID: 15800956
14. Rotman Y, Liang TJ (2009) Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 83: 7366-7374. doi: 10.1128/JVI.00191-09 PMID: 19420073
15. Mandorfer M, Payer BA, Niederecker A, Lang G, Aichelburg MC, et al. (2014) Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS Patient Care STDS 28: 221-227. doi: 10.1089/apc.2013.0359 PMID: 24796757
16. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K (2011) Increasing burden of liver disease in patients with HIV infection. Lancet 377: 1198-1209. doi: 10.1016/S0140-6736(10)62001-6 PMID: 21459211
17. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, et al. (2005) Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 19: 2117-2125. doi: 10.1097/01.aids. 0000194799.43799.ea PMID: 16284461
18. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, et al. (2007) Liver-related mortality in humanimmunodeficiency- virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 14: 183-188. doi: 10.1111/j.1365-2893. 2006.00791.x PMID: 17305884
19. Dimitroulis D, Valsami S, Spartalis E, Pikoulis E, Kouraklis G (2013) Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus. World J Hepatol 5: 323-327. doi: 10.4254/wjh.v5.i6.323 PMID: 23805356
20. Nunnari G, Berretta M, Pinzone MR, Di Rosa M, Berretta S, et al. (2012) Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 16: 1257-1270. PMID: 23047511
21. Uchino K, Tateishi R, Nakagawa H, Shindoh J, Sugawara Y, et al. (2013) Uninodular combined hepatocellular and cholangiocarcinoma with multiple non-neoplastic hypervascular lesions appearing in the liver of a patient with HIV and HCV coinfection. J Clin Virol 57: 173-177. doi: 10.1016/j.jcv.2013.01.012 PMID: 23434197
22. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC (2009) The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 6: 573-582. doi: 10.1038/nrgastro.2009.149 PMID: 19724251
23. Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383: 1749-1761. doi: 10.1016/ S0140-6736(14)60121-5 PMID: 24480518
24. Castiella A, Zapata E, Alustiza JM (2010) Non-invasive methods for liver fibrosis prediction in hemochromatosis: One step beyond. World J Hepatol 2: 251-255. doi: 10.4254/wjh.v2.i7.251 PMID: 21161006
25. Frulio N, Trillaud H, Perez P, Asselineau J, Vandenhende M, et al. (2014) Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients. BMC Infect Dis 14: 405. doi: 10.1186/1471-2334-14-405 PMID: 25041708
26. Yoshioka K, Hashimoto S, Kawabe N (2014) Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res.
27. Anadol E, Schierwagen R, Elfimova N, Tack K, Schwarze-Zander C, et al. (2014) Circulating miRNAs as marker for liver injury in HIV patients. Hepatology.
28. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, et al. (2013) Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 58: 234-239. doi: 10.1016/j.jhep.2012.10.015 PMID: 23085648
29. Jansen C, Eischeid H, Goertzen J, Schierwagen R, Anadol E, et al. (2014) The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. PLoS One 9: e103779. doi: 10.1371/journal.pone.0103779 PMID: 25068403
30. Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, et al. (2014) MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis. J Gastroenterol Hepatol 29: 121-127. doi: 10.1111/jgh.12362 PMID: 24033414
31. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, et al. (2013) Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 49: 3442-3449. doi: 10.1016/j.ejca.2013.06.002 PMID: 23810247
32. Lee CH, Kim JH, Lee SW (2014) The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 52: 445-451. doi: 10.1007/s12275-014-4267-x PMID: 24871972
33. Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, et al. (2014) Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int.
34. Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, et al. (2014) Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. Cancer Sci.
35. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6: e23937. doi: 10.1371/ journal.pone.0023937 PMID: 21886843
36. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, et al. (2011) Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 9: 602-608 e601. doi: 10.1016/j.cgh.2011.03.002 PMID: 21397726
37. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, et al. (2013) Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62: 1634-1641. doi: 10.1136/gutjnl-2012-304038 PMID: 23250049
38. Casu S, Berzigotti A, Abraldes JG, Baringo MA, Rocabert L, et al. (2014) A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. Liver Int.
39. Fernandes FF, Ferraz ML, Andrade LE, Dellavance A, Terra C, et al. (2014) Enhanced Liver Fibrosis Panel as a Predictor of Liver Fibrosis in Chronic Hepatitis C Patients. J Clin Gastroenterol.
40. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, et al. (2012) von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 56: 1439-1447. doi: 10.1002/hep.25806 PMID: 22532296
41. Jansen C, Leeming DJ, Mandorfer M, Byrjalsen I, Schierwagen R, et al. (2014) PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension. PLoS One 9: e108544. doi: 10.1371/journal.pone.0108544 PMID: 25265505